Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.41 | 0.37 | 5.67 | 5.17 |
| FCF Yield | -6.57% | -6.34% | -3.82% | -3.39% |
| EV / EBITDA | -8.74 | -8.86 | -11.51 | -8.91 |
| Quality | ||||
| ROIC | -72.34% | -46.76% | -48.74% | -36.94% |
| Gross Margin | 0.00% | 23.33% | 100.00% | 24.88% |
| Cash Conversion Ratio | 0.58 | 0.63 | 0.47 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -25.73% | – | 27.03% |
| Free Cash Flow Growth | -18.13% | 4.36% | -31.50% | 20.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 0.07 | 0.88 | 2.21 |
| Interest Coverage | 0.00 | 0.00 | -133.41 | -40,794.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.91 | 0.00 |
| Cash Conversion Cycle | -5,179.05 | 2.27 | -2,702.73 | -128.93 |